Use the hyperlinks, where available to access additional clinical trial information.
An Open label, Multicentre, Phase I study of Ibrutinib and 3rd Party EBV specific T cells in Patients with immunosuppression related EBV-positive Brain and/or Systemic B cell lymphomas, that are relapsed/refractory or unsuitable for standard first-line treatments
Other Non-Commercial Sponsor
National Health & Medical Research Council (NHMRC)
This is a non-randomised trial, in which eligible patients will receive 560mg of oral Ibrutinib daily and four closely HLA matched third-party EBV-specific cytotoxic t-lymphocyte (CTL) infusions once a week at weeks 10, 11, 12 and 13.